Article in Cellular and molecular gastroenterology and hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Y ShimizuDepartment of Medicine, Los Angeles, California.
J Sinnett-SmithDepartment of Medicine, Los Angeles, California; Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; CURE: Digestive Diseases Research Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
M TenggaraDepartment of Medicine, Los Angeles, California.
M G MartinDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; VA Greater Los Angeles Health Care System, Los Angeles, California.
E RozengurtDepartment of Medicine, Los Angeles, California; Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; CURE: Digestive Diseases Research Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. Electronic address: erozengurt@mednet.ucla.edu.
Funding
Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
COngenital Diarrhea and Enteropathy (PediCODE) Consortium and BioRepositoryRC2DK118640 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI James Richard Goldenring, Izumi Kaji · 2019 to 2026
$14.8M
Intestinal Stem Cell Culture and Entero-Endocrine Lineage DevelopmentU01DK085535 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUNN, JAMES C, MARTIN, MARTIN G · 2009 to 2018
$3.7M
Limited Competition for the Continuation of the Intestinal Stem Cell Consortium Coordinating CenterU24DK085532 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NILAND, JOYCE CAROL · 2019 to 2023
$2.3M
PKD1 Signaling and Crosstalk Mechanisms in Intestinal Epithelial Cell RegulationR01DK100405 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 2014 to 2017
$1.3M
Identification of the growth-promoting PKD/YAP axis as a novel target for the statins in intestinal epithelial cells.I01BX003801 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI ROZENGURT, JUAN ENRIQUE · 2018 to 2021
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Protein Kinase D1 (PKD1) Signaling Induces Growth-Promoting Effects in Murine Enteroids. · full record | OpenQuestion